Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK, Ward MA, Garofalo D, Ahmed HV, McRoy L, Laney J, Zanotti G, Braverman J, Yu H, Feinberg BA. Kish JK, et al. Among authors: zanotti g. Breast Cancer Res. 2018 May 2;20(1):37. doi: 10.1186/s13058-018-0958-2. Breast Cancer Res. 2018. PMID: 29720233 Free PMC article. Clinical Trial.
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Wells JC, Graham J, Beuselinck B, Bjarnason GA, Donskov F, Hansen AR, McKay RR, Vaishampayan U, De Velasco G, Duh MS, Huynh L, Nguyen C, Zanotti G, Ramaswamy K, Choueiri TK, Heng DYC. Wells JC, et al. Among authors: zanotti g. Clin Genitourin Cancer. 2020 Aug;18(4):e350-e359. doi: 10.1016/j.clgc.2019.12.007. Epub 2019 Dec 13. Clin Genitourin Cancer. 2020. PMID: 31926879
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Bell T, Crown JP, Lang I, Bhattacharyya H, Zanotti G, Randolph S, Kim S, Huang X, Huang Bartlett C, Finn RS, Slamon D. Bell T, et al. Among authors: zanotti g. Curr Med Res Opin. 2016 May;32(5):959-65. doi: 10.1185/03007995.2016.1157060. Epub 2016 Mar 2. Curr Med Res Opin. 2016. PMID: 26894413 Clinical Trial.
Real-world patient- and caregiver-reported outcomes in advanced breast cancer.
Lambert-Obry V, Gouault-Laliberté A, Castonguay A, Zanotti G, Tran T, Mates M, Lemieux J, Chabot P, Prady C, Couture F, Lachaine J. Lambert-Obry V, et al. Among authors: zanotti g. Curr Oncol. 2018 Aug;25(4):e282-e290. doi: 10.3747/co.25.3765. Epub 2018 Aug 14. Curr Oncol. 2018. PMID: 30111973 Free PMC article.
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC. Graham J, et al. Among authors: zanotti g. Eur Urol Oncol. 2021 Feb;4(1):102-111. doi: 10.1016/j.euo.2019.11.001. Epub 2019 Nov 28. Eur Urol Oncol. 2021. PMID: 31786162
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Chang R, Duh MS, Heng DYC. Savard MF, et al. Among authors: zanotti g. Oncologist. 2020 May;25(5):422-430. doi: 10.1634/theoncologist.2019-0605. Epub 2020 Jan 23. Oncologist. 2020. PMID: 31971318 Free PMC article.
386 results